Annexon (NASDAQ:ANNX) highlighted progress across three programs targeting the classical complement pathway during a fireside chat at TD Cowen’s 46th Annual Healthcare Conference, with President and ...

The classical complement pathway typically requires antigen—antibody complexes (immune complexes) for activation (specific immune response), whereas the alternative pathway can be activated by C3 ...

Lead antibody MB0109 targets C1q and uniquely inhibits both classical complement cascade and C1q-mediated macrophage/microglial activation — two key drivers of neuroinflammationMB0109 demonstrated ...

Dianthus Therapeutics, Inc. (DNTH) is advancing its potential best-in-class complement inhibitor drug DNTH103 for a wide variety of autoimmune disorders. In particular, it is looking at advancing the ...

“After more than a decade of groundbreaking research targeting the early classical complement pathway, we are excited to have reached an important step in the clinical development of ANX1502, our ...

Cold agglutinin disease (CAD) is a rare subtype of autoimmune haemolytic anaemia (AIHA) where autoantibodies, predominantly of the IgM class, bind to red blood cells at reduced temperatures. This ...

Opportunities in the C5 inhibitors market include developing next-gen biosimilars and biosuperiors to improve administration frequency and expand treatment indications for diseases like aHUS, SCD, MG, ...

Target Levels of Active Drug Achieved in Healthy Volunteers with Oral Twice-Daily Dosing; Supportive Impact on Pharmacodynamic Biomarker of Complement Activity ANX1502 Generally Well Tolerated Across ...